| __timestamp | BioMarin Pharmaceutical Inc. | Merck & Co., Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 302156000 | 11606000000 |
| Thursday, January 1, 2015 | 402271000 | 10313000000 |
| Friday, January 1, 2016 | 476593000 | 9762000000 |
| Sunday, January 1, 2017 | 554336000 | 9830000000 |
| Monday, January 1, 2018 | 604353000 | 10102000000 |
| Tuesday, January 1, 2019 | 680924000 | 10615000000 |
| Wednesday, January 1, 2020 | 737669000 | 8955000000 |
| Friday, January 1, 2021 | 759375000 | 9634000000 |
| Saturday, January 1, 2022 | 854009000 | 10042000000 |
| Sunday, January 1, 2023 | 937300000 | 10504000000 |
| Monday, January 1, 2024 | 1009025000 |
Cracking the code
In the ever-evolving pharmaceutical industry, understanding the financial strategies of leading companies is crucial. Over the past decade, Merck & Co., Inc. and BioMarin Pharmaceutical Inc. have showcased distinct approaches in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Merck's SG&A expenses have consistently dwarfed those of BioMarin, averaging around 10 times higher. This reflects Merck's expansive global operations and robust marketing strategies. However, BioMarin's SG&A expenses have shown a steady growth, increasing by approximately 210% over the same period, indicating its strategic investments in niche markets and innovative therapies. As of 2023, BioMarin's SG&A expenses reached nearly 940 million, while Merck's stood at over 10.5 billion. These spending patterns highlight the contrasting business models and growth trajectories of these pharmaceutical powerhouses.
Johnson & Johnson and Merck & Co., Inc.: SG&A Spending Patterns Compared
Johnson & Johnson and BioMarin Pharmaceutical Inc.: SG&A Spending Patterns Compared
AbbVie Inc. and BioMarin Pharmaceutical Inc.: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Merck & Co., Inc. vs Takeda Pharmaceutical Company Limited Trends and Insights
Breaking Down SG&A Expenses: Merck & Co., Inc. vs Verona Pharma plc
Operational Costs Compared: SG&A Analysis of Merck & Co., Inc. and Celldex Therapeutics, Inc.
Comparing SG&A Expenses: Merck & Co., Inc. vs Xencor, Inc. Trends and Insights
Cost Management Insights: SG&A Expenses for Bristol-Myers Squibb Company and BioMarin Pharmaceutical Inc.
Breaking Down SG&A Expenses: United Therapeutics Corporation vs BioMarin Pharmaceutical Inc.
Breaking Down SG&A Expenses: BioMarin Pharmaceutical Inc. vs Ultragenyx Pharmaceutical Inc.
BioMarin Pharmaceutical Inc. vs Grifols, S.A.: SG&A Expense Trends
Selling, General, and Administrative Costs: BioMarin Pharmaceutical Inc. vs Ligand Pharmaceuticals Incorporated